RXi Pharmaceuticals to Webcast Presentation at the 9^th Annual BIO Investor Forum

September 30, 2010

WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that the Company’s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 9^th Annual BIO Investor Forum on Wednesday, October 6, 2010 at 2:30 p.m. PT in San Francisco.

A live webcast of the presentation will be available from the “Investor Relations” section of the Company's redesigned website, www.rxipharma.com, which will be launched next week. A replay of the presentation will be available for 30 days.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. www.rxipharma.com

 

CONTACT:

RXi Pharmaceuticals

Donna Falcetti

508-929-3615

ir@rxipharma.com

 

or

 

Investors

S. A. Noonan Communications

Susan Noonan

212-966-3650

susan@sanoonan.com

 

or

 

Media

Rx Communications Group

Eric Goldman

917-322-2563

egoldman@rxir.com